Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 901–1,000 of 1,448
Pinçon, A., Thomas, M. H., Huguet, M., Allouche, A., Colin, J. C., Georges, A., Derrien, A., Lanhers, M.-C., Malaplate-Armand, C., Oster, T., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142127 · Cited by 19
“the processing and clearance of A peptides [16–18],”
Mouse models of neurological disorders: A view from the blood–brain barrier
Banks, W. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.011 · Cited by 23
P-Tau as prognostic marker in long term follow up for patients with shunted iNPH
Migliorati, K., Panciani, P. P., Pertichetti, M., Borroni, B., Archetti, S., Rozzini, L., Padovani, A., di Bergamo, L. T., Bruscella, S., & Fontanella, M. M. (2020) · Neurological Research · doi:10.1080/01616412.2020.1831300 · Cited by 22
Han, M., Seo, H., Choi, H., Lee, E., & Park, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.685977 · Cited by 23
“Furthermore, expression of AQP-4, which supports perivascular fluid and solute movement along the glymphatic system (Thrane et al., 2014; Smith et al., 2017), was investigated at 48 h after FUSinduced BBBD, to examine the molecular changes.”
BackgroundOshima, K., Akiyama, H., Tsuchiya, K., Kondo, H., Haga, C., Shimomura, Y., Iseki, E., Uchikado, H., Kato, M., Niizato, K., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0070-z · Cited by 25
Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease
Montalto, M., Farrar, G., & Hehir, C. A. T. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.023 · Cited by 22
Autophagy in alzheimer disease pathogenesis and its therapeutic values
Angst, G., Jia, N., Esqueda, L. T., Fan, Y., Cai, Q., & Wang, C. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2471677 · Cited by 27
Contributions of Drug Transporters to Blood-Brain Barriers
Liu, L., & Liu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_9 · Cited by 22
Guan, P.-P., Yang, L., Xu, G., & Wang, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158185 · Cited by 21
Hunt, N. J., Wahl, D., Westwood, L. J., Lockwood, G. P., Couteur, D. G. L., & Cogger, V. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114537 · Cited by 22
“It has been shown that the first step in the systemic clearance of Aβ is its uptake into hepatocytes by the low-density lipoprotein receptor-related peptide 1 [50].”
BackgroundLiu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
“This leads to an imbalance of Aβ in the periphery and the brain, promotes the outflow of soluble Aβ from the CNS via LRP-1 expressed on the BBB, and indirectly reduces the Aβ load in the brain [88, 89].”
BackgroundGenetic Animal Models of Cerebral Vasculopathies
Lee, J. H., Bacskai, B. J., & Ayata, C. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00002-0 · Cited by 24
Xu, G., Green, C. C., Fromholt, S. E., & Borchelt, D. R. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt110 · Cited by 22
“Both of these proteins are ligands of LRP1 and have been reported to mediate the clearance of Ab [13,16-19].”
Copeland, C., & Stabenfeldt, S. E. (2020) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2020.04.001 · Cited by 23
Gut Microbiota and Immunotherapy for Alzheimer’s Disease
Dai, C., Liu, F., Iqbal, K., & Gong, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315230 · Cited by 25
Soriano, F. X., Galbete, J. L., & Forloni, G. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00008-1 · Cited by 22
Qu, H. Y., Zhang, T., Li, X. L., Zhou, J. P., Zhao, B. Q., Li, Q., & Sun, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.109 · Cited by 21
Neuroinflammation and Alteration of the Blood-Brain Barrier in Alzheimer´s Disease
Soto-Rojas, L. O., de la Cruz‐López, F., Ontiveros‐Torres, M. Á., Viramontes‐Pintos, A., Cárdenas‐Aguayo, M. D. C., Meraz‐Ríos, M. A., Salinas‐Lara, C., Florán, B., & Luna‐Muñoz, J. (2015) · InTech eBooks · doi:10.5772/60024 · Cited by 23
Brzdak, P., Nowak, D., Wiera, G., & Mozrzymas, J. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00178 · Cited by 21
“Several studies have utilized specific antibodies or antagonists that block the ligand binding site (Shibata et al., 2000; Yamada et al., 2008).”
BackgroundPiwnica-Worms, D. R., Kesarwala, A. H., Pichler, A., Prior, J. L., & Sharma, V. (2006) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2006.06.007 · Cited by 22
Pan, T.-T., Sun, Y., Shi, Y.-F., Zhao, M., Khan, N. U., Chen, H., Ji, W., Li, J., Han, L., & Ma, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01840-5 · Cited by 21
“Intravenously delivered S@A-NPs penetrate the brain and distribute in the endothelial cells LRP1 is expressed on the luminal and abluminal membrane of brain microvascular endothelial cells [8, 30, 31].”
InfluentialFu, W., & Ho, P. C. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103058 · Cited by 21
Cerebral amyloid angiopathy distribution in older people: A cautionary note
Alakbarzade, V., French, J. M. R., Howlett, D. R., Attems, J., Francis, P. T., Stratton, S., Clark, C. N., Pereira, A. C., & Hainsworth, A. H. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12145 · Cited by 22
Gong, M., & Jia, J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.949129 · Cited by 20
Vascular endothelial cells: a fundamental approach for brain waste clearance
Wei, H., Jiang, H., Zhou, Y., Xiao, X., Zhou, C., & Ji, X. (2022) · Brain · doi:10.1093/brain/awac495 · Cited by 23
Ito, S., Yagi, R., Ogata, S., Masuda, T., Saito, T., Saido, T. C., & Ohtsuki, S. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00466-9 · Cited by 21
Amyloid-beta metabolism in age-related neurocardiovascular diseases
Aivalioti, E., Georgiopoulos, G. A., Tual‐Chalot, S., Bampatsias, D., Delialis, D., Sopova, K., Drakos, S. G., Stellos, K., & Stamatelopoulos, K. S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae655 · Cited by 24
“57 In pre-clinical murine models, low-density lipoprotein receptor-related protein-1 (LRP-1) and ApoE clear A β through BBB, 51 and conversely, the receptor for advanced glycation end products (RAGE) promotes the transportation of Αβ from the blood to the brain.”
InfluentialPérez‐Grijalba, V., Pesini, P., Allué, J. A., Sarasa, L., Montañés, M., Lacosta, A.-M., Casabona, D., José, I. S., Boada, M., Tárraga, L., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140156 · Cited by 23
O'Callaghan, P. W., Noborn, F., Sehlin, D., Li, J., Lannfelt, L., Lindahl, U., & Zhang, X. (2014) · Amyloid · doi:10.3109/13506129.2013.879643 · Cited by 21
Zhang, Y., Hodgson, N., Trivedi, M. S., & Deth, R. C. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3849087 · Cited by 21
Decreased Plasma Aβ in Hyperlipidemic APPSL Transgenic Mice Is Associated with BBB Dysfunction
Löffler, T., Flunkert, S., Temmel, M., & Hutter‐Paier, B. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00232 · Cited by 21
“Decreased plasma Aβ together with increased levels of insoluble Aβ and amyloid plaques in the brains of HFD fed APPSL mice point toward impaired Aβ clearance due to HFD. Additionally, HFD induced manifold alterations in the cerebral vasculature and BBB integrity exclusively in human APP overexpressing mice but not in…”
BackgroundInfluentialMcInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 22
When lipid homeostasis runs havoc: Lipotoxicity links lysosomal dysfunction to autophagy
Tegeder, I., & Kögel, D. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.11.005 · Cited by 22
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 21
Lu, Y., Barton, H. A., Leung, L. Y., Zhang, L., Hajós‐Korcsok, É., Nolan, C. E., Liu, J., Becker, S. L., Wood, K. M., Robshaw, A., et al. (2012) · Neurodegenerative Diseases · doi:10.1159/000341217 · Cited by 21
Effect of mouse strain as a background for Alzheimer’s disease models on the clearance of amyloid-β
Qosa, H., & Kaddoumi, A. (2016) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000123 · Cited by 22
“Aβ40 and Aβ42 share similar clearance pathway [16,17], however Aβ40 was used in the BCI% experiments because unlike Aβ42 it has lower tendency to aggregate and for practicality reasons as it has much faster clearance rate than Aβ42 [18,19].”
MethodThe Amyloid Hypothesis and the clearance and degradation of Alzheimer's β-peptide
LeVine, H. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6311 · Cited by 22
Possible Involvement of ER Chaperone Grp78 on Reduced Formation of Amyloid‐β Deposits
Kakimura, J., Kitamura, Y.-I., Takata, K., Tsuchiya, D., Taniguchi, T., Gebicke‐Haerter, P. J., Smith, M. A., Perry, G. L., & Shimohama, S. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04834.x · Cited by 25
Proust, A. M., Barat, C., Lebœuf, M., Drouin, J., Gagnon, M., Vanasse, F., & Tremblay, M. J. (2020) · Glia · doi:10.1002/glia.23833 · Cited by 21
“In contrast, capture of Aβ protofibrils was constantly decreased by RAP even in the absence of heparin (Figure 4e,f), indicating that this oligomeric form relies more on CD91 than on HSPG for its engulfment by astrocytes.”
BackgroundInfluentialQuan, W., Luo, Q., Hao, W., Tomic, I., Furihata, T., Schulz‐Schaeffer, W., Menger, M. D., Fassbender, K. C., & Liu, Y. (2021) · Glia · doi:10.1002/glia.24007 · Cited by 20
“LRP1 expression decreases in brain capillaries with aging and in AD (Shibata et al., 2000).”
BackgroundCallegari, K., Dash, S., Uchida, H., Shingai, Y., Liu, C., Khodarkovskaya, A., Lee, Y., Ito, A., Lopez, A., Zhang, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205786120 · Cited by 21
Interactions between Beta-Amyloid and Pericytes in Alzheimer’s Disease
Li, Y.-Y., Guo, D.-D., Duan, R., & Li, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904136 · Cited by 19
“A β is continuously generated by neurons and other cells in the healthy brain, and is subsequently cleared through various pathways [80–82] including receptor-dependent transport [80,83–86], cytosolic protease-mediated intracellular degradation [87] and glymphatic clearance [88].”
BackgroundHu, H., Wan, S., Hu, Y., Wang, Q., Li, H., & Zhang, N. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2445194 · Cited by 22
“Shibata [110] and Wilhelmus [111] confirmed that LRP1 is a primary receptor for the uptake and clearance of Aβ, participating in the absorption and clearance of the APOE– Aβ complex by astrocytes [112] and CVSMCs [98].”
Ovsepian, S. V., & Herms, J. W. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.005 · Cited by 22
“As a bona fide transcytotic process, LRP-mediated clearance of Ab requires its high-affinity binding to LRP followed by uptake and transport across the blood brain barrier and release into the blood (Shibata et al., 2000).”
Tachikawa, M., Uchida, Y., Ohtsuki, S., & Terasaki, T. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_2 · Cited by 23
Ito, S., Matsumiya, K., Ohtsuki, S., Kamiie, J., & Terasaki, T. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.125 · Cited by 19
Transport of Drugs Across the blood–brain Barrier in Alzheimer‘s Disease
Nicolazzo, J. A., & Mehta, D. C. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.41 · Cited by 22
Miyazaki, M., Malis, V., Yamamoto, A., Kungsamutr, J., McEvoy, L. K., McDonald, M. A., & Bae, W. C. (2023) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2023-0005 · Cited by 19
Kilian, J., Mejias‐Ortega, M., Hsu, H.-W., Herman, D. A., Vidal, J., Arechavala, R. J., Renusch, S. R., Dalal, H., Hasen, I., Ting, A., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad036 · Cited by 21
Erickson, M. A., & Mahankali, A. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126607 · Cited by 21
“In addition to transport in the blood-to-brain direction, substances can cross the intact BBB in the brain-to-blood direction, which is an important mechanism for the clearance of substances such as amyloid beta from the brain [75].”
BackgroundBello, I., & Salerno, M. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-014-0566-8 · Cited by 20
“This suppression of LRP1 expression could also attenuate the elimination of Aβ40, and therefore, unexpected gene modulation and consequent alteration of systemic Aβ clearance in the knockout mice could not be ruled out (Ito et al 2006).”
InfluentialKang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 21
“A RAGE inhibitor or an LRP-1 activator may be a potential candidate for AD treatment based on amyloid clearance.”
BackgroundInfluentialProgress Towards a Consensus on Biomarkers for Alzheimer‘S Disease: A Review of Peripheral Analytes
Rembach, A., Ryan, T. M., Roberts, B. R., Doecke, J. D., Wilson, W. J., Watt, A. D., Barnham, K. J., & Masters, C. L. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.59 · Cited by 20
Petrushina, I., Davtyan, H., Hovakimyan, A., Davtyan, A., Passos, G. F., Cribbs, D. H., Ghochikyan, A., & Agadjanyan, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.002 · Cited by 20
Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease
Kim, D., & Priefer, R. (2020) · Brain Sciences · doi:10.3390/brainsci10020093 · Cited by 20
“The apoE3 produces protective effects, such as phosphorylation of a tight junction protein and occludin on the BBB, and inhibits pericyte mobility from LRP1, but those effects are deficient in apoE4 [33].”
BackgroundInfluentialRodrigues, J. P., Prajapati, N., DeCoster, M. A., Poh, S., & Murray, T. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.019 · Cited by 19
Lazo, N. D., Maji, S. K., Fradinger, E. A., Bitan, G., & Teplow, D. B. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch17 · Cited by 19
Bondareff, W. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122305 · Cited by 22
Iurescia, S., Fioretti, D., Mangialasche, F., & Rinaldi, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100009 · Cited by 17
“As compared to adult wild-type mice, A β efflux is signifi-cantly reduced in young and old ApoE knockout mice, and in old wild-type mice [54].”
McInerney, M. P., Volitakis, I., Bush, A. I., Banks, W. A., Short, J. L., & Nicolazzo, J. A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2377-6 · Cited by 19
Novel ventriculoperitoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers
Silverberg, G. D., Mayo, M. R., Saul, T., Carvalho, J., & McGuire, D. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.1.97 · Cited by 22
Microtubular interactions of presenilin direct kinesis of Aβ peptide and its precursors
Tezapsidis, N., MERZ, P. A., Merz, G., & Hong, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0980fje · Cited by 19
“After internalization, Aβ itself is either degraded or transported through the cell, a process that is perhaps both cell specific (33) and apoE isoform specific (34).”
BackgroundAmyloid β Degradation: A Challenging Task for Brain Peptidases
Morelli, L., Bulloj, A., Leal, M. C., & Castaño, E. M. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_6 · Cited by 19
Bionanotechnologies for treatment and diagnosis of Alzheimer's disease
Moghimi, S. M. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.05.001 · Cited by 18
Zhao, D., Wang, J., Zhu, Y., Zhang, H., Ni, C., Zhao, Z., Dai, J., He, R., Liu, G.-Z., Gan, C., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00510-8 · Cited by 21
“In addition, the level of LDL receptor– related protein-1 mediating Aβ transport is also reduced [63, 64].”
Brain-targeted drug delivery by in vivo functionalized liposome with stable D-peptide ligand
Yang, Y., Chu, Y., Li, C., Fan, L., Lu, H., Zhan, C., & Zhang, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.014 · Cited by 18
Lyckenvik, T., Olsson, M. A., Forsberg, M., Wasling, P., Zetterberg, H., Hedner, J. A., & Hanse, E. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00698-x · Cited by 19
Vascular and non‐vascular contributors to memory reduction during traumatic brain injury
Charkviani, M., Muradashvili, N., & Lominadze, D. G. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14390 · Cited by 17
“, 1993) and clears brain derived Aβ (Shibata et al., 2000).”
BackgroundZaghmi, A., Drouin‐Ouellet, J., Brambilla, D., & Gauthier, M. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120461 · Cited by 17
Bajaj, S., Zameer, S., Jain, S., Yadav, V., & Vohora, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00699 · Cited by 19
Changes in the choroid plexuses and brain barriers associated with high blood pressure and ageing
González-Marrero, I., Hernández-Abad, L. G., Castañeyra-Ruiz, L., Carmona-Calero, E. M., & Castañeyra-Perdomo, A. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.05.007 · Cited by 23
Ueno, M., Wu, B., Nakagawa, T., Nagai, Y., Onodera, M., Huang, C., Kusaka, T., Kanenishi, K., & Sakamoto, H. (2010) · Histochemistry and Cell Biology · doi:10.1007/s00418-010-0705-y · Cited by 18
“LRP1 binds both ApoE/A complexes and A , and regulates their clearance from brain to blood (Shibata et al. 2000; Zlokovic 2004).”
BackgroundYamamoto, M., Kiyota, T., Walsh, S. M., & Ikezu, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9049-8 · Cited by 18
New pathways in drug discovery for alzheimer’s disease
Siemers, E., Dean, R. A., Demattos, R. B., & May, P. C. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0017-8 · Cited by 17
“Animal studies suggest that Aβ is actively transported from brain interstitial fluid into blood [ 16 ].”
BackgroundAzmi, N. H., Ismail, M., Ismail, N., Imam, M. U., Alitheen, N. B., & Abdullah, M. A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/153684 · Cited by 26
Yang, H., Hou, T., Wang, W., Luo, Y., Yan, F., & Jia, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171094 · Cited by 19
Kageyama, Y., Saito, A., Pletniková, O., Rudow, G. L., Irie, Y., An, Y., Murakami, K., Irie, K., Resnick, S. M., Fowler, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35004-3 · Cited by 19
Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Lee, H., Ugay, D. A., Hong, S., & Kim, Y. S. (2020) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2020.19.1.1 · Cited by 17
Insulin Resistance and Alzheimer’s Disease
Son, S. M., Joon, H. S., & Mook‐Jung, I. (2011) · InTech eBooks · doi:10.5772/23409 · Cited by 18
“, 2011); and 3) Receptormediated BBB transport by binding to low-density lipoprotein receptor-related protein-1 (LRP1) after ligation with apolipoprotein E (APOE) or ┙2-macroglobulin (┙2M), to be delivered to peripheral sites of degradation (Shibata et al., 2000).”
Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 16
Lin, Y., Yoo, J. M., Li, D., Heo, Y., Okumura, M., Won, H., Vendruscolo, M., Lim, M. H., & Lee, Y. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00507-3 · Cited by 17
“Moreover, insulin resistance also lowers the expression of low-density lipoprotein receptor-related protein 1, a transporter responsible for moving Aβ across the BBB, leading to reduced Aβ clearance [299–301].”
Inflammatory Cytokine IL-1β Downregulates Endothelial LRP1 via MicroRNA-mediated Gene Silencing
Hsu, H.-W., Rodríguez‐Ortiz, C. J., Zumkehr, J., & Kitazawa, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.021 · Cited by 17
“The number of mechanisms in the brain including, but not limited to, phagocytosis and containment by microglia (Lee and Landreth, 2010), antibody-mediated clearance (Wilcock et al., 2003), enzymatic degradation by neprilysin (NEP) and insulin degrading enzyme (IDE) (Jha et al., 2015), clearance by interstitial fluid,…”
BackgroundFrank, C. J., & McNay, E. C. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13074 · Cited by 17
“…reduced by blocking microglial activation Bailey et al. (2004)82 Review of the contributions of microvascular pathology to AD Nelson et al. (2017)85, Shibata et al. (2000)84 Aβ influx/efflux is dependent on BBB RAGE and LRP1/2 Zlokovic (2013)92 Review of the cerebrovascular effects of APOE4 Main…”
BackgroundBone Marrow‐Derived GCA+ Immune Cells Drive Alzheimer's Disease Progression
Zhou, R., Wang, L., Chen, L., Xu, F., Zhou, R., Peng, X. F., Wen, J., Huang, Y., & Zhou, H. (2023) · Advanced Science · doi:10.1002/advs.202303402 · Cited by 20
Oxidative stress is associated with Aβ accumulation in chronic sleep deprivation model
Beiyu, Z., Zhou, R., Zhao, Y., Wei, S., Peng, L., Meng, W., Peng, W., Yuan, Y., & Qu, Q. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148776 · Cited by 19
Tatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 17
Syndapin-2 mediated transcytosis of amyloid-β across the blood–brain barrier
Leite, D. M., Seifi, M., Ruiz‐Pérez, L., Nguemo, F., Plomann, M., Swinny, J. D., & Battaglia, G. (2022) · Brain Communications · doi:10.1093/braincomms/fcac039 · Cited by 16
“as a main transporter for Aβ.(11,14,15,17) It is thus safe to assume that decline in the expression of LRP1, reported with normal ageing and Alzheimer’s disease, results in a deficient Aβ clearance across the BBB.”
Lehmann, G. L., Ginsberg, M. D., Nolan, D. J., Rodríguez, C., Martínez‐González, J., Zeng, S., Voigt, A. P., Mullins, R. F., Rafii, S., Rodriguez-Boulan, E. J., et al. (2022) · Cells · doi:10.3390/cells11192975 · Cited by 17
“In addition, A2M interacts with βamyloid peptide inhibiting fibril formation [74,75] and promoting β-amyloid clearance from the brain [76].”
BackgroundADAMTS4 is involved in the production of the Alzheimer disease amyloid biomarker APP669-711
Matsuzaki, M., Yokoyama, M., Yoshizawa, Y., Kaneko, N., Naito, H., Kobayashi, H., Korenaga, A., Sekiya, S., Ikemura, K., Opoku, G., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01946-y · Cited by 17
Road to Alzheimer’s Disease: The Pathomechanism Underlying
Anand, R., Kaushal, A., Wani, W. Y., & Gill, K. D. (2011) · Pathobiology · doi:10.1159/000332218 · Cited by 24
Lipid metabolism in Alzheimer’s and Parkinson’s disease
Xu, Q., & Huang, Y. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.441 · Cited by 18
“Many hypotheses have been proposed, including the modulation of the deposition and clearance of Aβ and the formation of plaques [92–102], impairment of the antioxidative defense system [103–105], dysregulation of neuronal signaling pathways [106], disruption of cytoskeletal structure and function [107–109], and increa…”
BackgroundBanks, W. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-72573-4_4 · Cited by 17
Dissociation of ERK and Akt signaling in endothelial cell angiogenic responses to β-amyloid
Magrané, J., Christensen, R. A., Rosen, K. M., Veereshwarayya, V., & Querfurth, H. W. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.12.009 · Cited by 16
Ekuni, D., Endo, Y., Tomofuji, T., Azuma, T., Irie, K., Kasuyama, K., & Morita, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074966 · Cited by 17
“ApoE is involved in the clearance of Aβ from the central nervous system across the blood brain barrier [17,18].”
BackgroundCognitive behavioral therapy (CBT) for preventing Alzheimer’s disease
Reid, L. D., Avens, F. E., & Walf, A. A. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.024 · Cited by 20
“Modern research has discovered there are potentially multiple ways for clearing the brain of excess Ab (and potentially other proteins) including bulk flow at the B-NC interface [21], via other dura mater lymphatics [160,161], via glymphatic clearance [22] or by way of facilitated transport at the blood-brain barrier…”
Retinal Vascular Pathology in a Rat Model of Cerebral Small Vessel Disease
Scheifele, H. M., Arndt, P., Garz, C., Carare, R. O., Heinze, H., Schreiber, S., & Jandke, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00533 · Cited by 15
“Although studies in the early 2000s’ mainly focused on nonlymphatic Aβ clearance (49, 50), current research suggests that lymphatic Aβ drainage contributes to a larger portion than expected (51–53).”
BackgroundJeong, Y.-M., Lee, J. G., Cho, H.-J., Lee, W. S., Jeong, J., & Lee, J.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111883 · Cited by 14
Wang, J., Meng, X., Jialun, Y., Tang, Y., Zeng, F., Wang, Y., Chen, Z., Chen, D., Zou, R., & Liu, W. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04350-w · Cited by 15
Du, J., Sun, B., Chen, K., Zhang, L., Liu, S., Gu, Q., Li, F., Zhao, N., & Wang, Z. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005530 · Cited by 16
“Ab is generated from Ab precursor protein (APP) through two sequential proteolytic cleavages by b-secretase and c-secretase [18] and is cleared either through receptormediated efflux across the blood-brain barrier (BBB) [19,20] or via peptidolytic mechanisms [21].”
What Is the “Glymphatic System”?
Oshio, K. (2021) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.bc.2021-0059 · Cited by 15
“Some of the molecules, like amyloid β, are actively transported into the blood stream.(3) The 1Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan”
Background
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






